Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44551-44562

  Moran Jones, Kim ^a,b   Gloss, Brian S ^a,b   Murali, Rajmohan ^c   Chang, David K ^a   Colvin, Emily K ^d   Jones, Marc D ^a   Yuen, Samuel ^d   Howell, Viive M ^d   Brown, Laura M ^a   Wong, Carol W ^e   Spong, Suzanne M ^e   Scarlett, Christopher J ^a,f   Hacker, Neville F ^b   Ghosh, Sue ^g   Mok, Samuel C ^h   Birrer, Michael J ⁱ   Samimi, Goli ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e FIBROGEN INC   (United States)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

CTGF; FG 3019; Metastasis; Ovarian cancer; Tumor microenvironment

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; PAMREVLUMAB; ANTINEOPLASTIC AGENT; CTGF PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CLINICAL FEATURE; CONTROLLED STUDY; CTGF GENE; DRUG MECHANISM; EX VIVO STUDY; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR MODEL; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM ADHESION; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR ASSOCIATED FIBROBLAST; TUMOR MICROENVIRONMENT; VALIDATION PROCESS; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; GENETIC DATABASE; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PATHOLOGY; PERITONEAL NEOPLASMS; SECONDARY; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CONNECTIVE TISSUE GROWTH FACTOR; DATABASES, GENETIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SIGNAL TRANSDUCTION; STROMAL CELLS; UP-REGULATION;

EID: 84953409571     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6082     Document Type: Article

References (47)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
2. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004; 351:2519-2529.
3. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609-615.
4. Vang R, Shih Ie M and Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009; 16:267-282.
5. Shih IM and Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164:1511-1518.
6. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer. 2010; 10:803-808.
7. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334:1-6.
8. Parrott JA, Nilsson E, Mosher R, Magrane G, Albertson D, Pinkel D, Gray JW and Skinner MK. Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells. Mol Cell Endocrinol. 2001; 175:29-39.
9. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005; 7:513-520.
10. Brown TJ, Shaw PA, Karp X, Huynh MH, Begley H and Ringuette MJ. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol. 1999; 75:25-33.
11. Parrott JA, Kim G and Skinner MK. Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod. 2000; 62:1600-1609.
12. Doraiswamy V, Parrott JA and Skinner MK. Expression and action of transforming growth factor alpha in normal ovarian surface epithelium and ovarian cancer. Biol Reprod. 2000; 63:789-796.
13. Nilsson E, Doraiswamy V, Parrott JA and Skinner MK. Expression and action of transforming growth factor beta (TGFbeta1, TGFbeta2, TGFbeta3) in normal bovine ovarian surface epithelium and implications for human ovarian cancer. Mol Cell Endocrinol. 2001; 182:145-155.
14. Parrott JA and Skinner MK. Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer. Biol Reprod. 2000; 62:491-500.
15. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Gertig D, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008; 14:5198-5208.
16. Lili LN, Matyunina LV, Walker LD, Benigno BB and McDonald JF. Molecular profiling predicts the existence of two functionally distinct classes of ovarian cancer stroma. Biomed Res Int. 2013; 2013:846387.
17. Burns WC, Kantharidis P and Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs. 2007; 185:222-231.
18. Gore-Hyer E, Shegogue D, Markiewicz M, Lo S, Hazen-Martin D, Greene EL, Grotendorst G and Trojanowska M. TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol. 2002; 283:F707-716.
19. Phanish MK, Wahab NA, Colville-Nash P, Hendry BM and Dockrell ME. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J. 2006; 393:601-607.
20. Chen CC and Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol. 2009; 41:771-783.
21. Brigstock DR. The CCN family: a new stimulus package. J Endocrinol. 2003; 178:169-175.
22. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet. 2004; 363:62-64.
23. Koliopanos A, Friess H, di Mola FF, Tang WH, Kubulus D, Brigstock D, Zimmermann A and Buchler MW. Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg. 2002; 26:420-427.
24. Xie D, Nakachi K, Wang H, Elashoff R and Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 2001; 61:8917-8923.
25. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD and Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005; 65:8887-8895.
26. Aikawa T, Gunn J, Spong SM, Klaus SJ and Korc M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther. 2006; 5:1108-1116.
27. Dornhofer N, Spong S, Bennewith K, Salim A, Klaus S, Kambham N, Wong C, Kaper F, Sutphin P, Nacamuli R, Hockel M, Le Q, Longaker M, et al. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2006; 66:5816-5827.
28. Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM and Tuveson DA. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A. 2013; 110:12325-12330.
29. Mageto Y, Flaherty K, Brown K, Fong A and Raghu G. Safety and Tolerability of Human Monoclonal Antibody FG-3019, Anti-Connective Tissue Growth Factor, in Patients with Idiopathic Pulmonary Fibrosis. Chest. 2004; 26:7735-a.
30. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009; 16:521-532.
31. Auersperg N, Wong AS, Choi KC, Kang SK and Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001; 22:255-288.
32. Yokoyama Y, Sedgewick G and Ramakrishnan S. Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination. Cancer Res. 2007; 67:10813-10822.
33. Mizutani M, Ito Y, Mizuno M, Nishimura H, Suzuki Y, Hattori R, Matsukawa Y, Imai M, Oliver N, Goldschmeding R, Aten J, Krediet RT, Yuzawa Y and Matsuo S. Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. Am J Physiol Renal Physiol. 2010; 298:F721-733.
34. Gao R and Brigstock DR. A novel integrin alpha5beta1 binding domain in module 4 of connective tissue growth factor (CCN2/CTGF) promotes adhesion and migration of activated pancreatic stellate cells. Gut. 2006; 55:856-862.
35. Strobel T and Cannistra SA. Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol. 1999; 73:362-367.
36. Liotta LA and Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001; 411:375-379.
37. Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW and Koeffler HP. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res. 2005; 11:7243-7254.
38. Bartel F, Balschun K, Gradhand E, Strauss HG, Dittmer J and Hauptmann S. Inverse expression of cystein-rich 61 (Cyr61/CCN1) and connective tissue growth factor (CTGF/CCN2) in borderline tumors and carcinomas of the ovary. Int J Gynecol Pathol. 2012; 31:405-415.
39. Lawrenson K, Sproul D, Grun B, Notaridou M, Benjamin E, Jacobs IJ, Dafou D, Sims AH and Gayther SA. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. Carcinogenesis. 2011; 32:1540-1549.
40. Barbolina MV, Adley BP, Kelly DL, Shepard J, Fought AJ, Scholtens D, Penzes P, Shea LD and Stack MS. Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion. Int J Cancer. 2009; 125:816-825.
41. Sodek KL, Ringuette MJ and Brown TJ. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer. 2009; 124:2060-2070.
42. Kikuchi R, Tsuda H, Kanai Y, Kasamatsu T, Sengoku K, Hirohashi S, Inazawa J and Imoto I. Promoter Hypermethylation Contributes to Frequent Inactivation of a Putative Conditional Tumor Suppressor Gene Connective Tissue Growth Factor in Ovarian Cancer. Cancer Res. 2007; 67:7095-7105.
43. Zhang W, Liu Y, Sun N, Wang D, Boyd-Kirkup J, Dou X and Han JD. Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer. Cell Rep. 2013; 4:542-553.
44. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005; 65:10602-10612.
45. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ and Mok SC. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013; 19:809-820.
46. Asao T, Yazawa S, Kudo S, Takenoshita S and Nagamachi Y. A novel ex vivo method for assaying adhesion of cancer cells to the peritoneum. Cancer Lett. 1994; 78:57-62.
47. Samimi G, Ring BZ, Ross DT, Seitz RS, Sutherland RL, O'Brien PM, Hacker NF and Huh WK. TLE3 Expression Is Associated with Sensitivity to Taxane Treatment in Ovarian Carcinoma. Cancer Epidemiol Biomarkers Prev. 2012; 21:273-279.